| Similar Articles |
|---|
 |
The Motley Fool
January 27, 2005
Wherrett & Yelovich |
Billion-Dollar Markets Nanoparticulates offer golden opportunities for investors... if you know where to look.   |
Bio-IT World
March 8, 2005
Salvatore Salamone |
Nano Poised for Liftoff First 'nano' technologies yield fruit in the biomedical lab and clinic with the promise of more to come. |
Chemistry World
June 2011 |
Breaking through the barrier Getting drug molecules into the brain means crossing the defensive blood-brain barrier. Anthony King investigates how chemists are infiltrating the brain's fortress |
Chemistry World
July 28, 2009
Michael Gross |
DNA to direct and switch off chemo Researchers in the US have developed a new approach to cancer chemotherapy using short DNA strands to help target delivery of the drug directly to cancer cells, and 'call it off' should problems arise. |
Chemistry World
January 17, 2008
Lewis Brindley |
Nanomachines to Treat Cancer Scientists at the University of California-Los Angeles (UCLA) have signed a deal with a private investment firm to develop and market 'nanomachines' to treat cancer. |
The Motley Fool
October 10, 2006
Jack Uldrich |
Dow Chemical's Down-Under Investment Has Upside Potential The company's equity stake in an Australian nanotech company could pay big dividends. Investors, take note. |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
Chemistry World
April 19, 2011
Simon Hadlington |
Cell factories package drugs for delivery Scientists in Australia and Germany have used living cells as 'factories' to encapsulate particles such as drugs in biological membranes. |
The Motley Fool
July 12, 2010
Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. |
Pharmaceutical Executive
April 1, 2011 |
Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition. |
Pharmaceutical Executive
July 1, 2011
Dickmeyer & Rosenbeck |
From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition? |
BusinessWeek
May 27, 2010
Pettypiece & Gibson |
Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer." |
Pharmaceutical Executive
May 1, 2011
Jill Wechsler |
Outrage Over Drug Prices Stiff price tags draw scrutiny from Congress and consumers, and raise questions about FDA policies |
Chemistry World
September 26, 2006
Fiona Case |
Synchronised Delivery for DNA and Drugs Polymer capsules that can simultaneously deliver drug molecules and DNA into a cell could boost the power of cancer treatments. |
Chemistry World
July 2010
Hayley Birch |
Special Report: Health breakthroughs of the decade New discoveries have been made with cancer vaccines, genomics, statin drugs, allosteric modulators, and RNA interference during the last decade. |
Pharmaceutical Executive
October 1, 2010 |
Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Popular Mechanics
May 2006 |
Your Upgrade Is Ready: Photos and Animations Scientists have created stealth polymers that help fight cancer. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
August 31, 2010
Brian Orelli |
Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior. |
The Motley Fool
September 26, 2007
Brian Orelli |
4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies... |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
PC Magazine
July 13, 2004
Jim Akin |
Nanotechnology Size Matters Incubating inside this tiny world are some big ideas that could improve everything from manufacturing to health care. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Chemistry World
July 25, 2008
Olivia Walker |
Engineered antibodies could cut chemotherapy risks US scientists have cut the side-effects of cancer treatment in animal trials by carefully controlling the number of drug molecules attached to the antibodies used for chemotherapy. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Cancer: On Target Once More Over the past year or two, a handful of Phase III failures, including megablockbusters like Avastin and Sutent in trials for all kinds of common tumors, indicate that targeted therapy is generally a blunt instrument. |
The Motley Fool
March 30, 2010
Brian Orelli |
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. |
Chemistry World
November 4, 2010
Laura Howes |
Blocking cancer drug's toxic side effects US researchers have identified a compound that could drastically reduce toxic side effects associated with a widely used cancer drug. |
The Motley Fool
October 8, 2010
Luke Timmerman |
Onyx Delays Cancer Drug Application As FDA Asks for More Data Shares fell about 7% in after-hours trading Thursday evening. |
The Motley Fool
January 25, 2011
Brian Orelli |
2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
Chemistry World
January 6, 2011
Laura Howes |
Using HIV against itself US researchers have developed a 'Trojan horse' molecule that uses HIV to trigger the release of a drug that destroys the virus. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
December 29, 2009
Brian Orelli |
Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others. |
Managed Care
April 2004
Thomas Morrow |
Transdermal Patches Are More Than Skin Deep After modest beginnings, transdermal patches are now taking advantage of nanotechnology and other novel techniques to improve drug delivery. |
Technology Research News
July 27, 2005 |
Baited molecule fights cancer Many teams of researchers are working on ways to use nanotechnology to deliver anticancer drugs directly to cancerous tissue. |
The Motley Fool
February 8, 2011
Esterhuizen & Sellitti |
Battle of the Bulge: Biotech Takes on Obesity and Diabetes Will recent advances in pharmaceutical research revolutionize the weight loss industry? It's still early days, but here are some of the stocks to watch. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
The Motley Fool
September 28, 2010
Brian Orelli |
Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs. |
The Motley Fool
May 11, 2010
Ryan McBride |
Clinical Data Seeks to Challenge Lilly, Pfizer in Antidepressant Market The tiny drug developer has no problem going up against bigger rivals. |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. |
BusinessWeek
April 11, 2005
Arlene Weintraub |
A Nano Drug's Giant Promise After seeking FDA approval for a decade, American Pharmaceutical Partners' Abraxane, which offers a less-toxic cancer treatment, has doctors and investors hopeful. |
The Motley Fool
December 21, 2004
Charly Travers |
Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc. |
Chemistry World
December 2007
Derek Lowe |
Column: In the Pipeline The challenge of biologics. |
Chemistry World
April 2011 |
Molecular Obesity is Weighing Down Drug Discovery Medicinal chemistry's quest for potent drug candidates has resulted in molecules that are too large and too lipophilic for their own good. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
November 16, 2010
Luke Timmerman |
Dendreon Prepares to Take Some Heat Over Cancer Drug Prices Dendreon looking for off-label uses for its prostate cancer drug. |
The Motley Fool
July 30, 2010
Brian Orelli |
3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company. |
